Kristian N Jenssen

Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial

A. Fromm, H. Næss, J. Haasz, 2022, The Lancet Neurology.